Gryaznov Sergei 4

What Happened
Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, was granted a derivative award on April 10, 2026 representing the right to acquire 400,000 shares of MAIA common stock. The Form 4 records the acquisition amount as $0.00, reflecting an option/grant rather than a cash purchase.

Key Details

• Transaction date: 2026-04-10; Form 4 filed 2026-04-14 (timely within two business days).
• Transaction type/code: A (award/grant of a derivative security — stock options).
• Shares/options: 400,000-option grant reported. Reported cash amount: $0.00.
• Vesting: 4-year schedule — 25% vests on the first anniversary, remaining options vest ratably monthly over the next 36 months (per footnote).
• Shares owned after transaction: not specified in the provided filing.
• No 10b5-1 plan, tax-withholding, cashless exercise, or sale reported in this filing.

Context
This was an equity compensation grant (options) intended for future vesting and not an immediate market purchase or sale. Such grants are typically part of executive compensation and retention; they do not represent an immediate cash investment or disposition by the insider.